33 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
(R&D) services performed by Cocrystal and reimbursed by Merck.
As discussed above, in January 2021 Merck assumed all activities and expenses … on product sales.
R&D expenses for the third quarter of 2021 were $2.2 million compared with $2.1 million for the third quarter of 2020, with the increase
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
in the combined Company’s manufacturing and R&D facilities and drug development pipeline.
Mr. Prego-Novo stated, “This exciting acquisition enables the BioZone … and invest wisely in our manufacturing facilities, R&D laboratories and our robust drug pipeline. Moreover, I intend to draw on my experience and contacts
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
infections.
First Quarter 2022 Financial Results
Research and development (R&D) expenses for the first quarter of 2022 were $2.9 million compared … with $1.6 million for the first quarter of 2021, with the increase primarily related to COVID-19 and influenza programs. The Company expects R&D expenses
8-K
EX-99.1
arts58kby02azi 38p
7 Jan 19
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
9:03am
8-K
EX-99.1
dxr1be6wda
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
idjpoqrljawxl7xu0yc
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
pn3cw750kf2lvmwnk5j
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
0b4rdmoyhioop 3fj
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K/A
EX-99.1
1jxu5hz1pgp7h
20 Mar 14
Index to Financial Statements
12:00am
8-K
EX-99.1
atx0c
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
lhfyvx5
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am